Short Summary
The appellant filed an RTI seeking comprehensive information from ICMR regarding the legal framework, ownership, and formalities associated with protecting a Clinical Outcome Assessment (COA) tool developed by undergraduate students. The Commission found that the PIO had disclosed available public domain information, but directed ICMR to provide the Appellant with its detailed Intellectual Property Policy for complete transparency.
Detailed Summary
In the world of research and innovation, intellectual property is often treated as a closely guarded secret — locked behind institutional walls and legal jargon. But what happens when a curious student asks, in plain language, "How do I protect what we built?" That single question, filed as a Right to Information request, became the spark for a case that tested the boundaries of transparency in one of India's most important medical research bodies. This case is a reminder that for founders, researchers, and institutions alike, clarity around IP ownership isn't just a legal formality — it's a public interest issue.
The dispute centered on Hamrish Kumar Rajakumar, an appellant who sought detailed information from the Indian Council of Medical Research (ICMR) regarding the legal framework, ownership, and formalities associated with protecting a Clinical Outcome Assessment (COA) tool that had been developed by undergraduate students. Concerned about how such student-led innovations could be safeguarded, the appellant turned to the RTI Act to obtain clarity directly from the institution. The Public Information Officer (PIO) at ICMR responded by sharing whatever information was already available in the public domain. However, the appellant argued that this response was incomplete — the institution's own Intellectual Property Policy, which governed exactly the kind of questions he was asking, had not been disclosed.
On one side, the appellant contended that the ICMR's detailed Intellectual Property Policy was critical "information" under the RTI Act and should have been furnished in response to his request. He argued that without access to this internal policy, he could not fully understand the ownership and protection mechanisms available for a COA tool created by students. On the other side, the PIO maintained that the public domain information already provided was sufficient, implicitly suggesting that the IP Policy itself fell outside the scope of disclosable information. The legal friction, therefore, revolved around a fundamental question: does an institution's internal IP policy qualify as "information" that must be disclosed under transparency law, particularly when the subject matter — IP ownership in student research — touches on public interest?
The Commission examined the appellant's request and the PIO's response carefully. It acknowledged that the PIO had indeed disclosed the information available in the public domain. However, the Commission took a broader view of what constitutes relevant "information" under the RTI Act. It directed ICMR to provide the appellant with its detailed Intellectual Property Policy, ruling that such institutional policies and guidelines fall within the scope of disclosure when sought in connection with matters of public interest, including IP ownership in research. Despite this partial direction in favor of transparency, the overall outcome of the case was recorded as dismissed, reflecting the Commission's balancing of the appellant's right to information against the institution's procedural compliance.
For founders, research leaders, and IP professionals, this case carries a clear and practical lesson: institutional IP policies are not optional reading — they are public-interest documents that may be subject to disclosure. If your organization develops or funds research, particularly involving students or external contributors, your IP policy should be clear, accessible, and ready to be shared. More importantly, anyone building an innovative tool — especially in academic or collaborative settings — should proactively request and study the IP policies of the institutions they work with before assuming ownership or protection rights. Transparency isn't just a regulatory obligation; it's a foundation for trust, clarity, and fair innovation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Central Information Commission. Understanding the court's reasoning in Hamrish Kumar Rajakumar vs Indian Council of Medical Research (ICMR) is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
M/S M.M.I. Tobacco (P) Ltd.vsState Of U.P. And 11 Others
M/S M.M.I. Tobacco (P) Ltd. filed a writ petition seeking directions to state authorities to initiate proceedings against private respondents for alleged violations of the Trade Marks Act, 1999, and the Copyright Act, 1957. The petitioner sought mandatory action under both IP statutes. However, the Allahabad High Court dismissed the petition, holding that if any violation exists, the petitioner must pursue remedies through an FIR or other permissible legal actions, rather than seeking enforcement via writ jurisdiction.
Telefonaktiebolaget Lm Ericsson (Pub)vsThe Controller of Patents and Designs and Ors.
The appeal was filed by Telefonaktiebolaget Lm Ericsson against the Assistant Controller's refusal to grant a patent. The court found that there had been a violation of the principle of natural justice, specifically regarding the lack of opportunity for the appellant to deal with fresh objections.
Shantilal Paramshankar JoshivsThemis Distributors (P.) Limited
The plaintiff, a sole proprietor, claimed to be the inventor of a patented 'combined closure and dropper' device. He sued several defendants for infringing this patent. The court found that the plaintiff was the true and first inventor and ruled in favor of the plaintiff regarding infringement claims, while also dismissing appeals related to costs.
Otsuka Pharmaceutical Co LtdvsThe Controller General Of Patent Design and Trademarks And Anr
This case involves Otsuka Pharmaceutical Co Ltd appealing against a decision that was previously handled by the Intellectual Property Appellate Board (IPAB). Following the enactment of the Tribunals Reform Act, 2021, the matter was transferred to the Calcutta High Court. The court directed its Commercial Appellate Division to issue necessary notices and file a report before setting the next hearing date.
Adama India Private LimitedvsFmc Corporation & Anr.
Adama India Private Limited filed a suit seeking a declaration that its process for manufacturing Chlorantraniliprole (CTPR) does not infringe Patent No. IN 298645 held by FMC Corporation. The court, while addressing an interim application, granted a temporary restraint on the defendants from contacting distributors or regulatory authorities to prevent business hindrance.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.